Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Edesa Biotech, Inc. (EDSA)

Edesa Biotech raises base salaries for CEO, president and CFO, retroactive to July 1

Neutral Impact 3 of 5 leadership Written later

On October 23, 2026, Edesa Biotech's board approved base salary increases for CEO Pardeep Nijhawan, President Michael Brooks and CFO Peter Weiler, effective retroactive to July 1, 2026. The filing says the executives' base salaries had last been adjusted in 2023. The filing does not state the total added cost, but the raises are a higher fixed compensation expense for shareholders to consider.

Key points

  • CEO Pardeep Nijhawan's base salary rises from $357,696 to $657,423.
  • President Michael Brooks's base salary rises from $335,340 to $591,681; CFO Peter Weiler's rises from $300,000 to $525,938.
  • Increases are retroactive to July 1, 2026; prior adjustments were made in 2023.
  • 90% of Dr. Nijhawan's monthly base salary will continue to be paid in fully vested restricted share units under the 2019 Equity Incentive Compensation Plan.

The filing

CompanyEdesa Biotech, Inc. (EDSA)
Form8-K, current report
Filed with the SECOct 23, 2026, 5:24 PM ET
Accession number0001171843-26-006794

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 23, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.